



The annual report of the Australian IV safety company Medigard has just been published. It makes an interesting read as it helps to explain the complexities of product development of safety syringes and needlefree device products. These issues are explained in the product development section of the document on page 6 (example below):

“The fine tuning of the syringe design which was the focus of the past year has been completed and the result is an inexpensive, technically superior syringe that operates with vacuum and not a spring or sheath. Ease of use has been commented by all those who have trialed the product and its activation effort is significantly less than competitors spring products. That competitive advantage is strengthened by a lower cost to produce, a lack of aerosoling and the advantage of interchangeable needles.

The next steps for the syringe will be the preparation and submission of an application to the FDA. This will be preceded by relevant focus groups and simulated clinical trials. There is strong interest in the syringe and recognition that it is a leading edge product that fills the current and future market need a reliable, cheap, safe and user friendly syringe that automatically retracts with no dangerous spray and allows the interchangeability of needles”.

The annual report of the Australian IV safety company Medigard has just been published. It makes an interesting read as it helps to explain the complexities of product development of safety syringes and needlefree device products. These issues are explained in the product development section of the document on page 6 (example below):

“The fine tuning of the syringe design which was the focus of the past year has been completed and the result is an inexpensive, technically superior syringe that operates with vacuum and not a spring or sheath. Ease of use has been commented by all those who have trialed the product and its activation effort is significantly less than competitors spring products. That competitive advantage is strengthened by a lower cost to produce, a lack of aerosoling and the advantage of interchangeable needles.

The next steps for the syringe will be the preparation and submission of an application to the FDA. This will be preceded by relevant focus groups and simulated clinical trials. There is strong interest in the syringe and recognition that it is a leading edge product that fills the current and future market need a reliable, cheap, safe and user friendly syringe that automatically retracts with no dangerous spray and allows the interchangeability of needles”.

[Click here to view the full document.](#)“The fine tuning of the syringe design which was the focus of the past year has been completed and the result is an inexpensive, technically superior syringe that operates with vacuum and not a spring or sheath. Ease of use has been commented by all those who have trialed the product and its activation effort is significantly less than competitors’ spring products. That competitive advantage is strengthened by a lower cost to produce, a lack of aerosoling and the advantage of interchangeable needles. ”

The next steps for the syringe will be the preparation and submission of an application to the FDA. This will be preceded by relevant focus groups and simulated clinical trials. There is strong interest in the syringe and recognition that it is a leading edge product that fills the current and future market need “ a reliable, cheap, safe and user friendly syringe that automatically retracts with no dangerous spray and allows the interchangeability of needles”.

[Click here to view the full document.](#)

